Eli Lilly Presents First Ovarian Cancer Data for Investigational ADC
At ESMO 2026, Eli Lilly reported that sofe-M plus bevacizumab demonstrated a 79% confirmed objective response rate in platinum-sensitive ovarian cancer.
At ESMO 2026, Eli Lilly reported that sofe-M plus bevacizumab demonstrated a 79% confirmed objective response rate in platinum-sensitive ovarian cancer.